Table 2 Prevalence and severity of physical symptoms and psychological distress and efforts invested in the SDM process: correlations with decisional conflict (N = 117).

From: Decisional conflict and its determinants among patients with cancer undergoing immunotherapy combined with chemotherapy or targeted therapy: a cross-sectional study

Independent variables

Prevalence

Severity/levels

Correlations with decisional conflict

N (%)

Mean (SD)

r

Physical symptoms (0–10)

 Immunotherapy-related symptoms

  Pruritus

47 (40.2)

1.95 (2.61)

 − 0.08

  Rash

40 (34.2)

1.03 (2.04)

 − 0.01

  Dry skin

49 (41.9)

1.09 (2.05)

 − 0.1

  Diarrhea

20 (17.1)

1.17 (2.11)

 − 0.1

 Cancer-related symptoms (0–10)

  Pain

68 (58.1)

3.12 (3.31)

 − 0.21*

  Fatigue

93 (79.5)

4.06 (3.01)

 − 0.30**

  Poor appetite

79 (67.5)

3.27 (3.03)

 − 0.29**

  Sleep disturbance

92 (78.6)

4.05 (3.10)

 − 0.1

Psychological distress 0–10)

 Uncertainty

77 (65.8)

2.86 (2.73)

 − 0.39**

Effort invested in the SDM process (0–9)

114 (97.4)

5.56 (2.02)

0.20*

  1. Physical and psychological symptoms were measured using the NRS (Numerical Rating Scale); Effort invested in the SDM process was measured using the CollaboRate tool; Decisional conflict was measured using the SURE (SURE version of the Decisional Conflict Scale; SDM Shared decision making; Spearman’s correlation tests were conducted to determine potential factors related to decisional conflict.
  2. *p < 0.05, ** p < 0.01.
Back to article page